Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống
1
/ 557 trang
THÔNG TIN TÀI LIỆU
Cấu trúc
Foreword
Preface
Acknowledgments
Contents
Contributors
Part I
Chapter 1: Modern History of Tuberculosis Control in China
1.1 Recent History of Public Health in China
1.2 National TB Programs
1.2.1 The First National TB Program: 1978–1982
1.2.1.1 Special Projects in Direct-Controlled Municipalities
1.2.1.2 China’s Public Health in 1982
1.2.2 The Second National TB Program: 1982–1991
1.2.2.1 Special Projects in Direct-Controlled Municipalities
1.2.2.2 Third National Sampling Survey: 1990
1.2.3 The Third National TB Program: 1991–2000
1.2.3.1 Fourth National Sampling Survey: 2000
1.2.4 The Fourth National TB Program: 2000–2010
1.3 Areas for Improvement/Continuing Challenges
1.3.1 Higher Demand on TB Prevention and Control
1.3.2 There Is Increasing Demand for Expanded Service
1.3.3 Funds and Policy Are Required for Multidrug-Resistant TB
1.3.4 Drug Supply, Management, and Usage Need to Be Improved
1.3.5 The Public Awareness of TB Needs to Be Improved
1.4 Conclusion
References
Chapter 2: TB Control in Pakistan
2.1 Background
2.2 National Burden of Infectious Diseases
2.3 Burden of TB
2.4 Health Services in Pakistan
2.5 Public Health Interventions for TB Control in Pakistan
2.5.1 Phase I (1995–2000)
2.5.2 Phase II (2001–2005)
2.5.3 Phase III (2006–to Date)
2.5.3.1 Pursuing High-Quality DOTS Expansion
2.5.3.2 Addressing TB-HIV Co-infection
2.5.3.3 Addressing MDR-TB
2.5.3.4 Other Challenges
2.5.4 Contributing to Health System Strengthening
2.5.4.1 TB-Tobacco Interventions
2.5.4.2 Lung Health Interventions
2.5.5 Engaging All Care Providers
2.5.6 Empowering People and Communities with TB
2.5.7 Enabling and Promoting Research
2.6 Lessons Learned
References
Chapter 3: TB Control in South Africa
3.1 National History and Current Status of Infectious Diseases in South Africa
3.2 National Healthcare History, Practice, and Spending in South Africa
3.3 National Strategy with Regard to Research Support and Spending in South Africa
3.4 The Historical and Current Comparative Scale of the TB Epidemic in South Africa
3.5 Effective Public Health Measures: Lessons and Successes
3.6 Identifying Risks and Worst-Case Scenarios
3.7 Urgent Needs and Action Steps
References
Chapter 4: Tuberculosis Control in Hong Kong
4.1 Current Status of TB in Hong Kong
4.2 TB Control Measures
4.2.1 Case Finding
4.2.1.1 Passive Case Finding
4.2.1.2 Active Case Finding
4.2.1.3 Mass Screening
4.2.2 Effective Chemotherapy
4.2.3 Treatment of LTBI
4.2.4 BCG Vaccination
4.2.5 Health Education
4.3 A Stagnated Decline in TB Notification in Recent Decades
4.3.1 Aging of the TB Epidemics
4.3.2 Aging of the Population
4.3.3 Lifestyle and Socioeconomic Factors
4.3.4 Current Minor Factors That May Adversely Affect TB Control in the Future
4.3.4.1 TB–HIV
4.3.4.2 Emergence of M/XDR-TB
4.4 The Way Forward
References
Chapter 5: Breakthrough Strategy for TB Control in Indonesia
5.1 Background
5.1.1 National History and Current Status of Infectious Diseases in Indonesia
5.1.2 National Healthcare in Indonesia
5.1.3 National History and Current Status of TB
5.1.3.1 TB Epidemiology
5.1.3.2 The National TB Control Program (NTP)
5.2 Effective Control Measures: Lessons and Successes
5.3 Future Risks and Scenarios
5.4 Urgent Needs and Action Steps
5.5 Conceptualizing the Breakthrough Strategy
5.6 Summary
References
Chapter 6: TB Control in Nigeria
6.1 Introduction
6.2 Healthcare Financing in Nigeria
6.2.1 Tuberculosis Program Financing
6.3 Nigerian Healthcare Indicators
6.4 National TB Control Program in Nigeria
6.4.1 Introduction
6.4.2 History of the Nigerian TB Program
6.4.3 TB Control Activities in the Era of USAID/CIDA, The Global Fund, and Government Funding
6.4.4 TB Control Performance Indicators
6.4.5 TB/HIV Indicators
6.4.6 MDR-TB
6.5 Key Lessons Learned in the Implementation of the Stop TB Strategy
6.6 Challenges for Implementation of Stop TB Strategy
6.7 Future Risk and Urgent Interventions Required
References
Part II
Chapter 7: Diagnosis of Tuberculosis: Current Pipeline, Unmet Needs, and New Developments
7.1 Diagnosis of Latent TB
7.2 Diagnosis of Active TB
7.2.1 Pulmonary TB
7.2.1.1 Radiography
7.2.1.2 Smear Microscopy
7.2.1.3 Culture-Based Methods
7.2.1.4 Nucleic Acid Amplification Tests
7.2.2 Extrapulmonary TB
7.2.3 Other Developments and Prospects for a Point-of-Care Test
7.3 Need for New Tools
7.4 Conclusion
References
Chapter 8: Current Options in Treatment and Issues in Tuberculosis Care in Low- and Middle-Income Countries
8.1 Introduction
8.2 General Concepts of TB Treatment
8.2.1 Development of Modern TB Chemotherapy Regimens
8.2.2 Objectives of TB Treatment
8.2.3 How Drug Resistance Develops
8.2.4 Impact of Clinical History and Manifestations on Treatment
8.3 Treatment for New Patients with Known or Presumed Drug Susceptible TB
8.3.1 New Cases
8.3.2 New Cases in Regions with High Prevalence of Isoniazid Resistance but No Drug Susceptibility Testing (DST)
8.3.3 New Cases with HIV Coinfection
8.3.4 Limitations of the Standardized Regimen for New Patients
8.3.4.1 Long Duration
8.3.4.2 Multiplicity of Drugs
8.3.4.3 Adverse Reactions to Anti-TB Drugs
8.3.4.4 High Costs of Therapy
8.3.4.5 Poor Outcomes if New Cases Have Unsuspected Drug Resistance
8.4 Treatment for Patients with Known or Suspected Drug Resistant TB
8.4.1 Standardized Regimen for Previously Treated Patients
8.4.2 Treatment of MDR-TB
8.4.2.1 Choosing Drugs for Treatment of MDR-TB: The Concept of Drug Groups
8.4.2.2 Principles to Construct an Effective Regimen for MDR-TB
8.4.2.3 Limitations of Treatment of MDR-TB
8.4.3 Treatment of XDR-TB
8.5 Issues in the Organization and Delivery of Treatment
8.5.1 From Directly Observed Treatment (DOT) to Patient-Centered Treatment
8.5.2 Reducing Suffering and Socioeconomic Burden Under the End TB Strategy
8.6 Areas of Need
References
Chapter 9: DOT Status and Development in China
9.1 The History of Tuberculosis Chemotherapy in China
9.1.1 DOT Is Brought to Treatment Management of TB Patients
9.1.1.1 The Fully Supervised TB Management Program in Beijing
9.1.1.2 The Whole Course Management Chemotherapy Program in Shanghai
9.1.2 Application and Development of DOT Strategies
9.1.2.1 The Application of DOT Policy in TB Control Program
Protocols of DOT Implementation
Developed Combinations of Anti-TB Drugs
Project Cure Rates
9.1.2.2 Promotion and Development of the DOT Strategy in TB Control Program
9.1.3 DOT Strategic Planning
9.1.3.1 National Tuberculosis Control Program 1981–1990: Implementation of the Non-hospitalization Chemotherapy Policy and Adoption of Fully Supervised Treatment Measures
9.1.3.2 National Tuberculosis Control Program 1991–2000: Full Implementation of DOT as the Key to DOTS
9.1.3.3 National Tuberculosis Control Program 2001–2010: Continuing to Improve Effective Implementation of DOTS and DOT
9.2 Challenges for DOT Performance in China
9.2.1 Problems
9.2.2 Elements That Deter the Use of DOT in China
9.2.2.1 Regional Variation
9.2.2.2 Difficulties of Promoting DOT Among Patients
9.2.2.3 Total Implementation of DOT Will Increase the Burden on Both the Patient and the Healthcare System
9.3 Exploring the Proper Model for TB Patient Management in China
9.3.1 The New International Concept
9.3.2 Exploring a New Model of Management for Chinese TB Patients
9.3.2.1 Policy Adjustment
9.3.2.2 Research on New Management Strategies
E-Pill Box Technology
Short Message Service (SMS) Technology
References
Chapter 10: Drug-Resistant TB
10.1 The Rise of Drug-Resistant Tuberculosis
10.1.1 The Chinese DR-TB Epidemic
10.1.2 Development of Drug Resistance
10.1.2.1 Treatment Failures Leading to DR-TB
10.1.3 Transmission of DR-TB
10.1.3.1 Transmission Risk Factors
10.1.3.2 Host Factors
10.2 DR-TB Control Strategy
10.3 DR-TB Mortality
10.3.1 DR-TB Will Cost More Social Resources
10.3.2 Measures to Avoid the Occurrence of DR-TB
10.3.3 DR-TB: A Global Public Health Threat
10.3.3.1 Hazards DR-TB Poses to Human Health
10.4 Identification and Diagnosis of DR-TB
10.4.1 DR-TB Patient Diagnostic Strategy
10.4.1.1 Evaluations of Drug-Resistant TB Diagnostic Techniques and Methods
10.4.1.2 Sequence of Susceptibility Testing
10.5 Treatment of Patients with DR-TB
10.5.1 Chemotherapy
10.5.2 The Prognosis of Patients with DR-TB
10.5.3 Patient Care and Support
10.5.4 Infection Control in Patients
10.5.5 Quality and Supply of Drugs
10.6 Future Trend of Drug-Resistant TB
10.7 The Urgent Need for New Treatment Medicines
10.7.1 Sharp Increase in DR-TB
10.7.2 HIV Dual Infection with M. tuberculosis
10.7.3 Treatment of Latent TB Infection
10.7.4 Treatment of Childhood TB
References
Chapter 11: The MDR-TB Epidemic in China: The Changing Landscape, Cause Analysis, Government Response, Current Status, and Future Aspects
11.1 Introduction
11.2 Current MDR-TB Epidemic in China
11.3 Possible Causes for the Current MDR-TB Epidemic in China
11.4 Government Plans and Measures to Combat the MDR-TB Epidemic in the Context of the National TB Prevention and Control
11.4.1 Increasing the National Budget for the TB Control and Prevention
11.4.2 Specific Measures to Control the MDR-TB Epidemic
11.5 Current Status of the MDR-TB Control in China
11.5.1 Implement the International Standard MDR-TB Surveillance and Registry System Nationwide
11.5.2 Improve the Existing National TB Registry Information Management Systems by Gradually Adding Routine Monitoring of MDR-TB
11.5.3 Launch the Pilot Projects on MDR-TB Control That Can Be Followed by Nationwide Expansions
11.5.4 Combat the MDR-TB Epidemic with Advanced Medical Researches with New Diagnosis and Treatment Tools
11.5.5 Provide the National Guidelines for MDR-TB Control Policies and Medical Practices
11.6 The Future Prospect for MDR-TB Prevention and Control in China
References
Chapter 12: Treatment of TB and HIV Coinfection
12.1 Trends of TB/HIV
12.2 Pathogenesis of TB/HIV
12.2.1 Pathogenesis of HIV
12.2.2 The Influence of HIV on M. tuberculosis Infection
12.2.3 The Impact of M. tuberculosis on HIV Infection
12.3 Clinical Features of TB/HIV
12.3.1 Clinical Manifestations of TB/HIV
12.3.1.1 Extrapulmonary TB
12.3.2 Laboratory Tests
12.3.2.1 Pathogen Detection: HIV
12.3.2.2 Pathogen Detection: TB
12.3.3 Pulmonary Imaging
12.4 Diagnosis and Identification of TB/HIV
12.4.1 Diagnosis
12.4.1.1 Laboratory Tests
12.4.1.2 The Clinical Stages of HIV Infection
12.4.1.3 Diagnosis of TB/HIV
12.4.1.4 Diagnosis of DR-TB/HIV
12.4.2 Identification
12.4.2.1 HIV/AIDS Patients Coinfected with Extrapulmonary TB
12.5 Treatment of TB/HIV
12.5.1 Treatment of HIV/AIDS
12.5.1.1 Antiretroviral Drugs
12.5.2 Treatment of TB
12.5.3 Treatment of TB/HIV
12.5.3.1 Interactions Between ART and Anti-TB Drugs Affect Drug Selection
12.5.3.2 Application of Glucocorticoids
12.5.3.3 The Treatment of Immune Reconstitution Syndrome
12.5.3.4 Course of Treatment
12.5.4 Preventive Anti-TB Treatment
12.6 Adverse Reactions and Monitoring in TB/HIV Combination Therapy
12.6.1 Treatment of Adverse Reactions
12.6.2 Monitoring the Combination Therapy
12.7 Collaborative TB/HIV Treatment
References
Chapter 13: Concurrence of Tuberculosis and Other Major Diseases
13.1 Concurrence of Tuberculosis and Diabetes
13.1.1 Pathogenesis of TB/Diabetes
13.1.2 Diagnosis of TB/Diabetes
13.1.3 Treatment of TB/Diabetic Patients
13.2 Silicosis and TB
13.2.1 Pathogenesis of Concurrence of Silicosis and TB
13.2.2 Diagnosis and Identification of Silicon TB
13.2.3 Treatment of Silicon TB
13.3 Combined Pulmonary Infection
13.3.1 Clinical Types of Combined Pulmonary Infection and Pathogen Distributions
13.3.1.1 Lung Structural Damage
13.3.1.2 Hospital-Acquired Pneumonia (HAP)
13.3.1.3 Immunosuppression
13.3.1.4 Aspiration pneumonia (AP)
13.3.1.5 Pulmonary TB Combined with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
13.3.2 Diagnosis of TB-Combined Pulmonary Infection
13.3.2.1 Confirmation of TB-Combined Pulmonary Infection
13.3.2.2 Etiological Diagnosis
Sputum
Imaging
Etiology Examination
13.3.2.3 Evaluation of the Clinical Significance of Pathogen Positive Results
Confirmation of Pathogen Diagnosis
Prompt Etiological Diagnosis
Diagnosis of Unknown Pathogen
13.3.3 Choice of Antibiotic(s) for Treatment of Lung Infection
13.3.3.1 Community-Acquired Pneumonia (CAP)
TB Patients Coinfected with Mild Pulmonary Infections
TB Patients Coinfected with Severe Pulmonary Infections
Course of Antibiotic Treatment
13.3.3.2 Hospital-Acquired Pneumonia (HAP)
13.3.3.3 Pneumonia in the Immunocompromised Host
Bacterial Infections
P. jirovecii Pneumonia (PCP)
Cytomegalovirus Pneumonia
Invasive Pulmonary Mycosis
13.3.3.4 Aspiration Pneumonia
13.3.3.5 Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
Antibiotics Indications for AECOPD
Risk Factors for P. aeruginosa Infection of COPD
Application of Antibiotics
13.3.3.6 MDR Infection
13.3.3.7 Treatment Failure
13.3.4 Respiratory Failure
13.3.4.1 Airway Control
13.3.4.2 Oxygen Therapy
13.3.4.3 Increasing Ventilation and Reducing Carbon Dioxide Retention
Application of a Respiratory Stimulant
Mechanical Ventilation
13.3.4.4 TB Conditions and Ventilation Strategies
Severe TB Patients with Bronchial Pulmonary Structural Damage
Immunosuppression in TB Combined with Secondary Lung Infection
Bronchopleural Fistula
TB and AECOPD
Bronchial Asthma with Pulmonary TB
13.3.4.5 Balancing the Acid–Base Ratio and Solving the Electrolyte Turbulence Problem
13.3.4.6 Treatment of Predisposing Factors and Basic Diseases
13.3.4.7 Preventing Complications
13.3.4.8 Nutritional Support
Increasing Caloric Intake
Increasing Protein Intake
Increasing Vitamin Intake
References
Chapter 14: Surgery for Pulmonary Tuberculosis and Its Indications
14.1 History of Surgery for Pulmonary Tuberculosis patients
14.1.1 PTB Surgery and Chemotherapy
14.2 Indications for PTB Surgery
14.3 Contraindications for PTB Surgery
14.4 Preoperative Preparation
14.5 Methods of PTB Surgery
14.5.1 Surgical Anesthesia
14.5.2 Laboratory Tests for Specimens after Surgery
14.6 The Complications and Treatment after Surgery
14.6.1 The Postoperative Mortality
14.6.2 Common Complications and Treatments
14.7 Postoperative Treatment and Prognosis
References
Chapter 15: Diagnosis and Interventional Therapy by Bronchoscopy
15.1 The History of Bronchoscopy
15.2 Indications and Contraindications for Flexible Bronchoscopy in TB Patients
15.2.1 Indications
15.2.2 Contraindications
15.3 Flexible Bronchoscopy Operation Procedures
15.3.1 Preparation
15.3.2 Anesthesia
15.3.3 Bronchoscopy
15.3.4 Post Bronchoscopy
15.4 Diagnosis of Bronchial Tuberculosis (BTB) via Bronchoscopy
15.4.1 Epidemiology of BTB
15.4.2 Common Inspection Methods
15.4.3 Bronchoscopy Complications
15.5 Flexible Bronchoscopy for Interventional Treatment of BTB
15.5.1 Drug Delivery by Bronchoscopy
15.5.2 Thermal Treatments for BTB
15.5.3 Cryotherapy
15.5.4 Stent Treatment
15.5.5 Balloon Dilation
15.5.5.1 Indications
15.5.5.2 Contraindications
15.5.5.3 Expansion Therapy Method
15.5.5.4 Complications
15.6 Summary
References
Chapter 16: Intensive Care Treatment of Critical Tuberculosis
16.1 Introduction
16.2 Candidates for TB Intensive Care Unit Treatment
16.2.1 TBICU Admission Criteria
16.2.2 Critical TB Patients in the TBICU
16.2.3 APACHE II Scoring System for TB Patients with Respiratory Failure
16.3 TBICU Requirements
16.4 Monitoring of Critical TB
16.4.1 Routine Clinical Monitoring
16.4.1.1 Symptoms
Coughing and Expectoration
Dyspnea
Chest Pain
16.4.1.2 Physical Signs
16.4.1.3 Fluid Intake and Output
16.4.2 Nutritional Status Monitoring
16.4.3 Brain Function Monitoring
16.4.4 Monitoring of Respiratory Function
16.4.4.1 Lung Capacity Monitoring
16.4.4.2 Lung Function Monitoring
16.4.4.3 Pulmonary Ventilation Function Monitoring